NOVO-B Stock Analysis

<div class='circular--portrait' style='background:#FF9E01;color: white;font-size:3em;padding-top: 40px;;'>NOV</div>
Is it time to take over Novo Nordisk? Novo Nordisk Stock analysis can help investors discover the best opportunities and time the market in virtually any economy. Find the stocks trading at a discount of their intrinsic value will give you an edge in creating a market-bitting portfolio. The current investor indifference towards the small price fluctuations of Novo Nordisk B AS may encourage investors to take a closer look at the firm as it closed today at a share price of 0.0 on very low momentum in trading volume. The company executives did not add any value to Novo Nordisk B investors in March. However, most investors can still diversify their portfolios with Novo Nordisk B AS to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. Check out Stocks Correlation.
View Stock Analysis For
The Novo Nordisk Stock analysis interface makes it easy to digest most current publicly released information about Novo Nordisk as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. NOVO-B stock analysis module also helps to analyze Novo Nordisk price relationship with some important fundamental indicators such as market cap and management efficiency.

NOVO-B Stock Analysis Notes

The company has Price/Earnings To Growth (PEG) ratio of 2.84. Novo Nordisk B recorded earning per share (EPS) of 15.88. The entity last dividend was issued on Augustust 16, 2019. The firm had 5:1 split on 2014-01-02. Novo Nordisk AS, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. Novo Nordisk operates under Pharmaceuticals And Biosciences classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 42453 people. To find out more about NOVO NORDISK -B- contact the company at 45 44 44 88 88 or learn more at http://www.novonordisk.com.

Novo Nordisk B Investment Alerts

Novo Nordisk B is not yet fully synchronised with the market data
Novo Nordisk B has some characteristics of a very speculative penny stock
Novo Nordisk B has high likelihood to experience some financial distress in the next 2 years
The company has accumulated 4.32 B in total debt with debt to equity ratio (D/E) of 9.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Novo Nordisk B has Current Ratio of 0.94 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.

Market Capitalization

The company currently falls under 'Mega-Cap' category with current market capitalization of 779.65 B.


The company has Profit Margin (PM) of 33.56 % which can be a sign that it executes well on its competitive strategies and has a good control over its expenditures. This is very large. Similarly, it shows Operating Margin (OM) of 42.94 % which suggests for every 100 dollars of sales it generated a net operating income of 0.43.

Management Efficiency

Novo Nordisk B has return on total asset (ROA) of 30.09 % which means that it generated profit of $30.09 on every $100 spent on asset. This is very large. Similarly, it shows return on equity (ROE) of 83.71 % meaning that it generated $83.71 on every $100 dollars invested by stockholders.

Institutional Stock Holders for Novo Nordisk

At Risk
OMX COPENHAGEN 0.12 (5.62) 
OMX Nordic 40 0.07 (5.87) 
STXE 50 PR EUR 0.0097 (7.29) 
Nasdaq Victory Intl Multi Fact 0.07 (21.80) 
Dorsey Wright Country And Stock 0.0212 (4.43) 
Nasdaq Future Global Sustainabi 0.11 (6.91) 
Nasdaq Victory International 50 0.0082 (4.82) 
Nasdaq Victory International 50(0.12) (27.68) 
Nasdaq Riskalyze Developed Mark 0.19 (7.22) 
Nasdaq Victory International 50 0.0043 (5.30) 
NASDAQ Europe Large Mid Cap NTR 0.0077 (6.45) 
OMX CopenhagenPI 0.10 (5.71) 
OMX Copenhagen BenchmarkPI 0.13 (5.02) 
OMX Copenhagen BenchmarkGI 0.14 (5.02) 
OMX Copenhagen 20 0.14 (3.41) 
Nasdaq Future Global Sustainabi 0.11 (6.75) 

Novo Nordisk Technical and Predictive Indicators

Did you try this?

Run ETF Directory Now


ETF Directory

Find actively-traded Exchange Traded Funds (ETF) from around the world
All  Next Launch Module
Check out Stocks Correlation. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Company logos by clearbit
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page